Abline Tirkey, Dilendra Chandraker*, Saurav Gosh and Neha Khan


From the past decade it has been noticed that human health is highly affected by numerous existing life forms, which results in illness and disease. Certain medications are used to cure the disease conditions. In order to provide immunity to health, vaccines are invented and introduced. As said, prevention is better than cure, the vaccines are highly used medication which protects the body by networking an immune system prior to the attack of infectious agents. Vaccine is a type of biological preparation against a particular infectious disease, providing active acquired immunity to an individual. Based on the presence of active component of antigen that generates a specific immune response, the vaccine can be broadly classified as a whole pathogen vaccine, live attenuated vaccine, inactivated vaccine, subunit vaccine, recombinant protein vaccine, conjugate vaccine, outer membrane vesicles vaccine, nucleic acid vaccine, RNA vaccine, DNA vaccine etc. Before coming in use, the vaccine undergoes many stages of research and testing. Under regular circumstances, the process takes an average of 15-20 years, which is a long period of time. In the case of pandemics, numerous strategies are made which possible the process to move from each stages as quickly as possible. Being testable does not mean that vaccine will be successful. The samples which are regarded as safe and easily replicable can proceed to clinical testing; while other working laboratories remain continue to explore more alternatives.

Keywords: Coronavirus, Diagnosis RT-PCR, True Nat, Antigen test, and Victimization.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    NOVEMBER 2022 Issue has been successfully launched on 1 NOVEMBER 2022.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction